0803 GMT - Bayer shares are likely to react positively to the German agricultural and pharmaceutical group's third-quarter results, analysts at J.P. Morgan say in a research note. The company lifted its underlying Ebitda guidance due to a better-than-expected performance in its pharma division, and its new outlook points to upgrades to consensus expectations, the analysts say. Moreover, both sales and underlying Ebitda for the third quarter exceeded consensus expectations. "Overall, we expect the results to be well received given the pharma-driven Ebitda beat and guidance raise, and expect the shares to outperform today by 2-3%," they add.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments